2211 - 2220 of 8571 Results
Title
Year
-
OPENTitle: Elucidating the importance and regulation of key enhancers for human MEIS1 expressionJournal Name: LeukemiaPublisher: Springer Science and Business Media LLCVol: 36Issue #: 8Start Page: 1980End Page: 1989Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41375-022-01602-4Best OA location URL: https://www.nature.com/articles/s41375-022-01602-4.pdfCitation Count: 3
-
RESTRICTEDTitle: From the prodromal stage of multiple sclerosis to disease preventionJournal Name: Nature Reviews NeurologyPublisher: Springer Science and Business Media LLCVol: 18Issue #: 9Start Page: 559End Page: 572Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/s41582-022-00686-xCitation Count: 24
-
RESTRICTEDTitle: The potential utility of smell testing to screen for neurodegenerative disordersJournal Name: Expert Review of Molecular DiagnosticsPublisher: Informa UK LimitedVol: 22Issue #: 2Start Page: 139End Page: 148Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14737159.2022.2037424Best OA location URL: https://qmro.qmul.ac.uk/xmlui/handle/123456789/76598Citation Count: 1
-
RESTRICTEDTitle: Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s diseaseJournal Name: Expert Review of NeurotherapeuticsPublisher: Informa UK LimitedVol: 22Issue #: 6Start Page: 489End Page: 498Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14737175.2022.2091436Citation Count: 4
-
RESTRICTEDTitle: Investigational therapeutics for the treatment of progressive supranuclear palsyJournal Name: Expert Opinion on Investigational DrugsPublisher: Informa UK LimitedVol: 31Issue #: 8Start Page: 813End Page: 823Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/13543784.2022.2087179Citation Count: 1
-
RESTRICTEDTitle: Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?Journal Name: NeuropharmacologyPublisher: Elsevier BVVol: 64Issue #:Start Page: 566End Page: 578Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2012.06.020Best OA location URL: https://europepmc.org/articles/pmc3725288?pdf=renderCitation Count: 206
-
RESTRICTEDTitle: Pharmacological interventions for psychosis in Parkinson’s disease patientsJournal Name: Expert Opinion on PharmacotherapyPublisher: Informa UK LimitedVol: 19Issue #: 5Start Page: 499End Page: 505Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14656566.2018.1445721Citation Count: 27
-
RESTRICTEDTitle: The Endo-lysosomal System in Parkinson’s Disease: Expanding the HorizonJournal Name: Journal of Molecular BiologyPublisher: Elsevier BVVol: 435Issue #: 12Start Page: 168140End Page: 168140Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jmb.2023.168140Best OA location URL: https://doi.org/10.1016/j.jmb.2023.168140Citation Count: 9
-
RESTRICTEDTitle: Gene therapy to target ER stress in brain diseasesJournal Name: Brain ResearchPublisher: Elsevier BVVol: 1648Issue #:Start Page: 561End Page: 570Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.brainres.2016.04.064Citation Count: 31
- Correction to Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase2019RESTRICTEDTitle: Correction to Conversion of Quinazoline Modulators from Inhibitors to Activators of β-GlucocerebrosidaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 62Issue #: 5Start Page: 2850End Page: 2850Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.9b00284Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00284Citation Count: 0